We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.60 | -0.65% | 91.30 | 91.12 | 91.90 | 92.24 | 91.09 | 91.83 | 891,417 | 16:40:00 |
From May 2021 to May 2024
By Giulia Petroni
The European Medicines Agency said Thursday that it has approved two additional manufacturing sites for the production of the Covid-19 vaccine developed by Pfizer Inc. and BioNTech SE.
The sites, which will manufacture the finished product, are set to provide up to 50 million additional doses of Comirnaty by 2021, according to the EU agency.
One site is operated by Sanofi-Aventis Deutschland GmbH, while the other by Siegfried Hameln GmbH. They are both located in Germany.
The European Medicines Agency said the sites can become operational immediately, as the recommendation doesn't require a decision from the European Commission.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
September 09, 2021 12:41 ET (16:41 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
